Renata PLC

RENATA

BD0457RENAT6

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
759.9 ^BDT	-3.00%		-5.06%	-37.61%

Feb. 13	Renata Limited will Change its Name to Renata PLC	CI
Jan. 27	Renata Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Renata Limited Recommends Dividend for the Year Ended June 30, 2020

October 27, 2020 at 11:04 am EDT

The board of directors of Renata Limited has recommended 130% cash dividend for the year ended on June 30, 2020.

Latest news about Renata PLC

Renata Limited will Change its Name to Renata PLC	Feb. 13	CI
Renata Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Jan. 27	CI
Renata Limited Announces Consent for Issuance of Secured, Non-Convertible Zero Coupon Bond	Jan. 23	CI
Renata Limited Proposes Cash Dividend for the Year Ended June 30, 2023	23-10-22	CI
Renata Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	23-10-21	CI
Renata Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-04-28	CI
Renata Limited Announces Management Changes	23-02-27	CI
Renata Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-01-30	CI
Renata Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	22-10-29	CI
Renata Limited Recommends Dividend for the Year Ended June 30, 2022	22-10-23	CI
Renata Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-04-27	CI
Renata Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-01-31	CI
Renata Limited Reports Earnings Results for the First Quarter Ended September 30, 2021	21-11-14	CI
Renata Limited Recommends Dividend for the Year Ended on June 30, 2021	21-10-24	CI
Renata Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021	21-05-01	CI
Renata Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-02-01	CI
Renata Limited Reports Earnings Results for the First Quarter Ended September 30, 2020	20-11-14	CI
Renata Limited Recommends Dividend for the Year Ended June 30, 2020	20-10-27	CI
Renata Limited completed the acquisition of unknown remaining shares of Renata Oncology Limited.	20-07-25	CI
Renata Limited Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-06-13	CI
Renata Limited Reports Earnings Results for the Second Quarter Ended December 31, 2019	20-01-29	CI
Renata Limited Recommends Cash Dividend for the Year Ended on June 30, 2019	19-10-30	CI
Renata Limited Reports Earnings Results for the First Quarter Ended September 30, 2019	19-10-29	CI
Renata Limited signed an agreement to acquire unknown remaining shares of Renata Oncology Limited.	19-10-28	CI
Renata Ltd. Reports Earnings Results for the Third Quarter Ended March 31, 2019	19-04-27	CI

Renata PLC, formerly Renata Limited, is a Bangladesh-based pharmaceutical and animal health company. The Company is engaged in manufacturing, marketing and distribution of pharmaceutical, animal health products, oncology-based products, agro-based products, poultry products, and consumer products. The Company also engages in the business as traders, importers, exporters, commission agents of all kinds of goods and services, including pharmaceutical drugs and medicines. Its offerings include Algin Injection, Algin Syrup, Alphapress Tablet, Androcap Capsule, Becosules Capsule, Bredicon Tablet, Cabolin Tablet, Anorexon Tablet, Aquastar Growout Powder, Avinex Powder, Catophos Injection, Eggshell Tmo Powder, Ectorid Injection, Doxivet Powder, Fevenil Injection, Fluximine Injection, Cardipin Tablet, Cartilage Plus Tablet, and Diadin Injection, among others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

759.9 BDT

Average target price

1,109 BDT

Spread / Average Target

+45.94%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RENATA PLC	-37.61%	794M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Renata PLC

Equities

RENATA

BD0457RENAT6

Pharmaceuticals

Renata Limited Recommends Dividend for the Year Ended June 30, 2020

Latest news about Renata PLC

Chart Renata PLC

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals